XML 43 R32.htm IDEA: XBRL DOCUMENT v3.25.1
Debt - (Tables)
3 Months Ended
Mar. 31, 2025
Debt Instrument, Redemption [Line Items]  
Summary of liability for sale of future royalties

    

Three Months Ended March 31, 

Liability for sale of future royalties- (current and noncurrent)

2025

Beginning balance as of December 31, 2024

$

2,081,776

Less: Non-cash royalty revenue payable to Royalty Pharma

(32,974)

Plus: Non-cash interest expense recognized

49,661

Ending balance

$

2,098,463

Effective interest rate as of March 31, 2025

 

9.3%

2026 Convertible Notes  
Debt Instrument, Redemption [Line Items]  
Summary of convertible notes

    

March 31, 2025

December 31, 2024

Principal

$

287,500

$

287,500

Less: Debt issuance costs

 

(1,788)

 

(2,088)

Net carrying amount

$

285,712

$

285,412

Summary of interest expense recognized related to the Convertible Notes

Three Months Ended March 31, 

    

2025

2024

    

Contractual interest expense

$

1,069

$

1,076

Amortization of debt issuance costs

 

299

296

Total

$

1,368

$

1,372

Effective interest rate

 

1.9

%

1.9

%